POSTMENOPAUSAL BONE LOSS poses a significant
|
|
- Philip Parsons
- 6 years ago
- Views:
Transcription
1 X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(6): Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: /jc Effects of Potassium Alkali and Calcium Supplementation on Bone Turnover in Postmenopausal Women Khashayar Sakhaee, Naim M. Maalouf, Steven A. Abrams, and Charles Y. C. Pak Center for Mineral Metabolism and Clinical Research (K.S., N.M.M., C.Y.C.P.), University of Texas Southwestern Medical Center, Dallas, Texas ; and Department of Pediatrics (S.A.A.), Children s Nutrition Research Center, Baylor College of Medicine, Houston, Texas Potassium citrate may improve calcium balance by conferring an alkali load. Calcium supplementation slows postmenopausal bone loss by inhibiting PTH secretion. This study explores whether combined treatment with potassium citrate and calcium citrate is more effective than either agent alone in inhibiting bone loss. In a crossover study involving 18 postmenopausal women, the following treatments were compared: potassium citrate (4.3 g or 40 mmol/d), calcium citrate (800 mg or 20 mmol/d), combined treatment, and placebo. During the last 2 d of each 2-wk phase, serum and 24-h urine were collected for assessment of calcium metabolism, alkali load, and bone turnover markers. Compared with placebo, potassium citrate provided an alkali load and significantly decreased urinary calcium without changing serum PTH (spth) or bone turnover markers. Calcium citrate significantly increased absorbed calcium, marginally decreased spth, and significantly reduced bone resorption markers. Combined POSTMENOPAUSAL BONE LOSS poses a significant health problem, because it can lead to osteoporotic fractures, causing considerable morbidity and even death (1). Calcium supplements and alkali have been known to inhibit bone loss by separate physiological mechanisms. The main effect of calcium supplementation is the reduction of bone resorption resulting from the inhibition of PTH secretion (2, 3). Alkali therapy is believed to prevent bone loss by several mechanisms (4 6). It may inhibit osteoclastic bone resorption by a direct action of alkali (6). When given as a potassium salt, alkali may indirectly prevent bone resorption by reducing urinary calcium (4, 7, 8). There is also some evidence that alkali may stimulate bone formation (4, 9). Because these agents have different effects on bone, we explored whether the combined use of calcium and alkali might exert an additional bone-protective action. The present placebo-controlled, crossover study was undertaken to compare the effects of potassium citrate, calcium citrate, and potassium citrate plus calcium citrate on calcium metabolism, acid-base status, and markers of bone turnover in postmenopausal women. First Published Online March 8, 2005 Abbreviations: BAP, Bone-specific alkaline phosphatase; CTX, C- terminal telopeptide of type I collagen; GLA, osteocalcin; 25-OHD, 25- hydroxy vitamin D; 1,25(OH) 2 D, calcitriol; OHP, hydroxyproline; NTX, N-terminal telopeptide of type I collagen; spth, serum PTH. JCEM is published monthly by The Endocrine Society ( endo-society.org), the foremost professional society serving the endocrine community. treatment retained key features of potassium citrate and calcium citrate. However, more alkali was delivered than with potassium citrate alone, and absorbed calcium did not differ from calcium citrate alone. Compared with placebo, combined treatment increased urinary calcium, marginally reduced spth, provided a clear alkali load, and reduced the bone resorption markers serum type I collagen C-telopeptide and urinary N-telopeptide by 20.4% (P ) and 18.2% (P 0.005), respectively. A significant trend was noted for the decrease in bone resorption markers as treatment changed from placebo to potassium citrate to calcium citrate to combined treatment. In postmenopausal women, combined treatment with potassium citrate and calcium citrate inhibits bone resorption by providing an alkali load and increasing absorbed calcium. (J Clin Endocrinol Metab 90: , 2005) Subjects Subjects and Methods Eighteen healthy postmenopausal women participated in the study. Sixteen women were Caucasian, and two were Asian. The mean age was 58 yr (range, yr). Other demographic information and bone mineral density data are shown in Table 1. Two subjects had osteoporosis (defined by a T-score 2.5 at either the femoral neck or the lumbar spine); the remaining women did not. Excluded from the study were subjects with primary hyperparathyroidism, nephrolithiasis, gastrointestinal disease, hyperkalemia, and/or renal insufficiency (creatinine clearance 60 ml/min). The subjects were not taking any bone protective agents such as estrogen, bisphosphonates, selective estrogen receptor modulators, teriparatide, fluoride, and pharmacological doses of vitamin D preparations. None were treated with diuretics, anticonvulsants, or glucocorticoids. The Institutional Review Board of the University of Texas Southwestern Medical Center (Dallas, Texas) approved the study, and all subjects signed an informed consent for the study. Study protocol This study was a crossover double-blind trial. Participants underwent four phases of study in a random order, using a 4 4 Latin square randomization scheme developed by a statistician. Each phase was 2 wk in duration, with a washout period of 2 wk between phases. During the placebo phase, subjects took two tablets of calcium citrate placebo and two tablets of potassium citrate placebo twice daily, providing neither calcium nor potassium citrate. During the potassium citrate phase, each subject took two tablets of potassium citrate [1080 mg (10 meq) per tablet] and two tablets of calcium citrate placebo twice a day, to deliver a daily intake of 4.3 g (40 mmol) of potassium citrate. During the calcium citrate phase, subjects took two tablets of calcium citrate [200 mg (5 mmol) calcium per tablet] and two tablets of potassium citrate placebo twice daily, providing 800 mg (20 mmol) of calcium daily. During the combined potassium citrate-calcium citrate phase, subjects received two 3528
2 Sakhaee et al. K Citrate and Ca Citrate in Postmenopausal Women J Clin Endocrinol Metab, June 2005, 90(6): TABLE 1. Characteristics of study subjects tablets of potassium citrate and two tablets of calcium citrate twice a day, providing 4.3 g (40 mmol) of potassium citrate and 800 mg (20 mmol) of calcium per day. Calcium citrate (Citracal), potassium citrate (Urocit- K), and corresponding placebo tablets were provided by the Mission Pharmacal Co. (San Antonio, TX). In each study phase, subjects received study drug(s) for 14 d (d 1 14). Compliance with each of the study drugs was ascertained by pill count at the end of each phase. On d 8 11, subjects were instructed by a University of Texas Southwestern Medical Center General Clinical Research Center (GCRC) dietitian to rigidly follow a diet with a daily composition of approximately 60 g of protein, 400 mg (10 mmol) of calcium, 800 mg (26 mmol) of phosphorus, 2.3 g (100 mmol) of sodium, 2.3 g (60 mmol) of potassium, and 3 liters of fluids. This diet, called basal diet, corresponded in composition to the diet usually consumed by many subjects who do not take calcium supplements. During the last 3 d of the study (d 12 14), subjects were admitted to the GCRC where they received a constant metabolic diet of the same composition. On d 12 14, a fasting venous blood sample was obtained each day for the measurement of sodium, potassium, chloride, total carbon dioxide content, calcium, phosphorus, alkaline phosphatase, and creatinine. On d 13 and 14, a fasting venous blood sample was taken each day for the analysis of 25-hydroxyvitamin D (25-OHD), calcitriol [1,25-(OH) 2 D], PTH, serum cross-linked carboxy-terminal C-telopeptide of type I collagen (CTX), osteocalcin (GLA), and bone-specific alkaline phosphatase (BAP). Two 24-h urine samples were collected on d 13 and 14 for the measurement of calcium, ph, citrate, ammonium (NH 4 ), creatinine, sodium, potassium, calcium, magnesium, phosphorus, chloride, and markers of bone resorption, hydroxyproline (OHP), and cross-linked amino-terminal telopeptide of type I collagen (NTX). Fractional intestinal calcium absorption was determined by dual isotope technique using stable calcium isotopes: 2.5 mg of 42 Ca ( mmol) was infused iv, and 1 mg of 46 Ca (0.025 mmol) was given orally with 100 mg (2.5 mmol) of calcium in a synthetic meal replacing breakfast. Urine was collected over the ensuing 24 h. Urine samples were prepared for thermal ionization mass spectrometric analysis as previously described (10) by using an oxalate precipitation technique. Samples were analyzed for isotopic enrichment by using a Finnigan MAT 261 (Thermo Electron, Bremen, Germany) magnetic sector thermal ionization mass spectrometer. The fractional intestinal absorption of calcium was determined as the dose-corrected quotient of the oral to iv tracers in the 24-h urine (11). The precision of the estimate of fractional calcium absorption is 3 5% of the resulting measurement. Analytical procedures and calculations Mean SD n 18 Age (yr) Height (cm) Weight (kg) BMI (kg/m 2 ) L2 L4 BMD (g/cm 2 ) L2 L4 T-score Femoral neck BMD (g/cm 2 ) Femoral neck T-score BMI, Body mass index; BMD, bone mineral density; L2 L4, L2 L4 vertebrae. Serum electrolytes, calcium, phosphorus, alkaline phosphatase, and creatinine were analyzed as part of a systematic multichannel analysis (GCRC Core Laboratory using the SYNCHRON CX9 ALX system; Beckman Coulter, Inc., Fullerton, CA). Serum 25-OHD, 1,25-(OH) 2 D, PTH, and GLA were measured by respective ELISAs (ALPCO Diagnostics, Windham, NH). Serum CTX was quantitated by ELISA (CTX Serum CrossLaps, Nordic Bioscience Diagnostics A/S, Herlev, Denmark). Serum BAP was assessed by ELISA (Quidel Corp., San Diego, CA). Urinary OHP was determined colorimetrically (Hypronosticon kit, Organon Teknika, Durham, NC). Urinary NTX was assessed by ELISA (Osteomark NTx, OSTEX International, Inc., Seattle, WA). Urinary calcium was analyzed by using atomic absorption spectrophotometry. Urinary citrate was quantitated enzymatically by using reagents from Boehringer- Mannheim Biochemical (Indianapolis, IN). Urinary ammonium was determined by the glutamate dehydrogenase method. Absorbed calcium was calculated as the product of the fractional intestinal absorption of calcium and the total amount of calcium ingested (from diet and supplement). In each subject, mean values for various serum or urinary tests were taken in deriving the group mean. Samples for bone markers, intact serum PTH (spth), and vitamin D metabolites were batched, and measurements were performed at the end of the study. Statistical analysis The four groups were compared by repeated-measures ANOVA. Significant differences among treatment phases were further analyzed by comparisons between pairs of treatment, by use of contrasts constructed from the ANOVA models. By employing the Bonferroni inequality to adjust for multiple testing, six pairwise comparisons were assessed: a) potassium citrate vs. placebo, b) calcium citrate vs. placebo, c) calcium citrate vs. potassium citrate, d) combined treatment (potassium citrate plus calcium citrate) vs. calcium citrate, e) combined treatment vs. potassium citrate, and f) combined treatment vs. placebo. The effects of alkali and calcium on a basal diet were obtained from a) and b), respectively. c) compared potassium citrate with calcium citrate on a basal diet. The effect of alkali on a high calcium intake was provided by d), whereas that of calcium on a high alkali intake was derived from e). f) yielded the effect of both alkali and calcium on a basal diet. In addition, we tested for the existence of trend in the change in the markers of bone resorption as the drug treatment changed from placebo to potassium citrate to calcium citrate to the combined treatment (12). The level of significance was 0.05 for the overall (four group) and trend tests. Each pairwise comparison was made with a Bonferroniadjusted type I error of Statistical analysis was performed with SAS version 9.0 (SAS Institute, Cary, NC) and with S-PLUS version 6.2 (Insightful Corp., Seattle, WA). Results Compliance Mean compliance by pill count was 97.7% during each study phase. Serum electrolytes and creatinine and urinary volume, sodium, creatinine, and sulfate were not different among the four phases of the study (Table 2). Effect of potassium citrate Compared with placebo, potassium citrate significantly reduced urinary calcium [ (sd) to mg/d ( to mmol/d); P ] without significantly changing spth, vitamin D metabolites, fractional intestinal calcium absorption, or total calcium absorbed (symbol a in Table 3). Moreover, potassium citrate significantly increased urinary ph ( to ; P 0.001) and citrate and significantly decreased urinary ammonium (symbol a in Table 2). Urinary and serum markers of bone resorption and bone formation were not significantly altered (Table 4 and Fig. 1). Effect of calcium citrate Compared with placebo, calcium citrate significantly increased urinary calcium [ to mg/d ( to mmol/d); P ] and marginally reduced fasting spth (P 0.09), without significantly altering vitamin D metabolites or fractional intestinal calcium absorption (symbol b in Table 3). However, the total amount of calcium absorbed increased significantly [ to mg/d ( to mmol/d); P
3 3530 J Clin Endocrinol Metab, June 2005, 90(6): Sakhaee et al. K Citrate and Ca Citrate in Postmenopausal Women TABLE 2. Serum and urinary biochemistry Study phase Placebo K citrate Ca citrate K citrate Ca citrate ANOVA P value Serum Na (meq/liter) K (meq/liter) CI (meq/liter) Total CO 2 (meq/liter) Creatinine (mg/dl) Urine Total volume (liters/d) Creatinine (mg/d) Potassium (meq/d) a c d,f ph a c d,f Ammonium (meq/d) a 23 7 b,c 14 5 d,f Citrate (mg/d) a b d,e,f Sulfate (mmol/d) Data are presented as mean SD. ANOVA P value denotes the level of significance for the overall (four-group) comparison by repeated measures ANOVA. Multiply by 88.4 to convert values for serum creatinine to mol/liter. Statistical significance at P level is indicated by a K citrate vs. placebo, b Ca citrate vs. placebo, c Ca citrate vs. K citrate, d K citrate Ca citrate vs. Ca citrate, e K citrate Ca citrate vs. K citrate, and f K citrate Ca citrate vs. placebo ]. Urinary ph marginally increased, urinary citrate significantly increased, and ammonium significantly decreased (symbol b in Table 2). Urinary OHP and serum CTX significantly decreased, but urinary NTX did not change significantly (symbol b in Table 4 and Fig. 1). Serum bone formation markers (GLA and BAP) were not significantly altered. Compared with potassium citrate alone, calcium citrate resulted in a significantly higher urinary calcium and absorbed calcium [ to mg/d ( to mmol/d); P ], and lower spth ( vs pg/ml; P 0.005) (symbol c in Table 3). Moreover, it yielded lower urinary ph and higher urinary ammonium (Table 2). Markers of bone turnover were not significantly different (Table 4). Effect of combined potassium citrate and calcium citrate The comparison of combined treatment (potassium citrate plus calcium citrate) vs. calcium citrate alone allowed assessment of the effect of potassium citrate during a high calcium intake (shown by symbol d in the Tables). Serum calcium, fasting PTH, and 1,25-(OH) 2 D and total calcium absorbed did not differ between the two phases (Table 3). During combined treatment, urinary calcium was numerically lower but not significantly different from calcium citrate alone. Urinary ph and citrate were significantly higher, and urinary ammonium was lower than with calcium citrate alone (Table 2). There were no significant differences in the markers of bone turnover (Table 4). Comparison of combined treatment (potassium citrate plus calcium citrate) vs. potassium citrate yielded the effect of calcium citrate during a high alkali intake (shown by symbol e in the Tables). During combined treatment, serum calcium significantly increased [ to mg/dl ( to mmol/liter); P ] and fasting spth significantly decreased ( vs pg/ml; P 0.005) (Table 3). Urinary calcium increased significantly [ to mg/d ( to mmol/d); P 0.001]. Urinary citrate was significantly greater, urinary ph was numerically higher, and urinary ammonium was numerically TABLE 3. Calcium metabolism Study phase Placebo K citrate Ca citrate K citrate Ca citrate ANOVA P value Serum calcium (mg/dl) e,f Serum phosphorus (mg/dl) d,e,f Serum alkaline phosphatase (U/liter) Serum 25-OHD (ng/ml) Serum 1,25-(OH) 2 D (pg/ml) Serum PTH (pg/ml) c e 0.01 Urinary phosphorus (mg/d) b,c e,f Urinary calcium (mg/d) a b,c e,f Fractional intestinal calcium absorption (%) Absorbed calcium (mg/d) b,c e,f Data are presented as mean SD. ANOVA P values denote the level of significance for the overall (four group) comparison by repeated measures ANOVA. P was chosen as Bonferroni correction for multiple testing (0.05 of six tests ). To convert values to mmol/liter, for serum calcium multiply by 0.20, for serum phosphorus multiply by To convert values for PTH to pmol/liter, multiply by 0.102, and multiply by to convert values for urinary calcium to mmol/d. To convert values to pmol/liter for serum 1,25-(OH) 2 D, multiply by 2.6, and to nmol/liter for 25-OHD, multiply by Statistical significance at P level is indicated by a K citrate vs. placebo, b Ca citrate vs. placebo, c Ca citrate vs. K citrate, d K citrate Ca citrate vs. Ca citrate, e K citrate Ca citrate vs. K citrate, and f K citrate Ca citrate vs. placebo.
4 Sakhaee et al. K Citrate and Ca Citrate in Postmenopausal Women J Clin Endocrinol Metab, June 2005, 90(6): TABLE 4. Markers of bone turnover Study phase Placebo K citrate Ca citrate K citrate Ca citrate ANOVA P value Markers of bone resorption Urinary OHP (mg/d) b 19 6 f Urinary NTX (nmol BCE/mmol Cr) e,f Serum CTX (ng/ml) b f Markers of bone formation GLA (ng/ml) BAP (U/liter) Data are presented as mean SD. ANOVA P values denote the level of significance for the overall (four group) comparison by repeated measures ANOVA. P was chosen as Bonferroni correction for multiple testing (0.05 of six tests ). Multiply by 7.6 to convert values for urinary OHP to mol/d, and multiply by 0.17 to convert values for osteocalcin to nmol/ml. BCE, Bone collagen equivalents; Cr, creatinine. Statistical significance at P level is indicated by a K citrate vs. placebo, b Ca citrate vs. placebo, c Ca citrate vs. K citrate, d K citrate Ca citrate vs. Ca citrate, e K citrate Ca citrate vs. K citrate, and f K citrate Ca citrate vs. placebo. lower than in potassium citrate alone (Table 2). Urinary NTX was significantly lower (by 18%; P 0.007) on combined treatment (Fig. 1). Comparison of combined treatment (potassium citrate plus calcium citrate) vs. placebo yielded the effect of alkali and calcium given together during a basal diet (shown by symbol f in the Tables). During combined treatment, serum and urinary calcium were significantly higher, and fasting spth was marginally lower (P 0.08) than during the placebo phase (Table 3). However, serum 1,25-(OH) 2 D and fractional intestinal calcium absorption did not differ between the two phases. Nonetheless, the total amount of calcium absorbed was significantly increased [ to mg/d ( to mmol/d); P ]. Urinary ph and citrate were significantly higher, and urinary ammonium was significantly lower than during placebo (Table 2). All three markers of bone resorption decreased significantly (OHP by 9.5%, NTX by 18.1%, and CTX by 20.4%), although markers of bone formation did not change (Table 4 and Fig. 1). Tests of trend A trend in the change in markers of bone resorption as the drug treatment changed from placebo to potassium citrate to calcium citrate to the combined treatment was noted (Fig. 2). Each of the trend tests was statistically significant. The observed significances were for urinary NTX, less than for serum CTX (Fig. 2), and 0.01 for urinary OHP (data not shown). Discussion This study was undertaken to determine whether combined treatment with potassium citrate and calcium citrate is more effective than treatment with either agent alone in preventing bone loss of postmenopausal women. The results showed that combined treatment shared some, but not all, of the biochemical-metabolic effects of each agent. The use of potassium citrate as a bone protective agent is based on prior studies showing beneficial effects of alkali on three target organs. In the kidneys, alkali provided as a potassium salt has been reported to reduce urinary calcium by enhancing renal tubular reabsorption of calcium (4, 7, 8) possibly through activation of the epithelial calcium channel (13). In the intestinal tract, potassium citrate treatment has been reported to enhance calcium absorption among patients with distal renal tubular acidosis (14). In the skeletal tissue, the osteoclastic resorption is inhibited (9) and osteoblastic formation is stimulated by alkali (4, 9). In this study, potassium citrate delivered a moderate alkali load, commensurate with a significant rise in urinary ph and citrate and a decrease in ammonium (Table 2). Although the FIG. 1. The change from placebo in the bone resorption markers (urinary OHP, urinary NTX, and serum CTX) produced by potassium citrate alone, calcium citrate alone, and the combination of potassium citrate and calcium citrate. Statistical significance at P level is indicated by an asterisk.
5 3532 J Clin Endocrinol Metab, June 2005, 90(6): Sakhaee et al. K Citrate and Ca Citrate in Postmenopausal Women FIG. 2. Trend in the change in the bone resorption markers as the treatment changed from placebo to potassium citrate to calcium citrate to the combined treatment. A statistically significant trend was observed for urinary NTX (P 0.003) and CTX (P ). fasting serum bicarbonate did not change, it is likely that it rose transiently after each dose of potassium citrate, thus accounting for the significant increase in urinary ph. Moreover, urinary calcium declined by 35 mg/d (0.88 mmol/d) as reported earlier with potassium alkali but not with sodium alkali (7, 8). Fractional intestinal calcium absorption did not change, likely resulting in net calcium retention. However, no change in bone turnover markers occurred. Thus, the hypocalciuric action of potassium citrate was probably mainly renal in origin (15). The potentially retained calcium was probably insufficient to alter bone markers. The above findings differ from previous studies in which potassium alkali was shown to significantly alter bone turnover markers in postmenopausal women (4, 5). Although in our study the dietary protein intake was equivalent to the recommended daily allowance (RDA) of 0.8 g protein/kg d (Ref. 16; see the subjects in the previous reports had a much higher intake of protein, which could have delivered more acid load (17). The resulting stimulated state of osteoclastic bone resorption may have been more amenable to correction by alkali. Another potential explanation is the lower dose of potassium alkali used in the present study (40 meq/d, compared with meq/d used in previous studies). In the present study, the fractional intestinal calcium absorption was unaffected by alkali. Earlier reports had disclosed that alkali therapy increases intestinal calcium absorption among patients with distal renal tubular acidosis (14) but does not alter it in normal subjects and postmenopausal women (4, 8). Thus, the action of alkali on intestinal handling of calcium may depend on the prevailing state of acid-base balance. The classic physiological action of calcium supplementation on bone implicates parathyroid suppression from absorbed calcium, leading to inhibition of osteoclastic bone resorption (2, 3). In this study, urinary OHP and serum CTX significantly decreased during calcium supplementation, although urinary NTX did not change (Table 4). These results are consistent with the prior reports on the effect of calcium supplementation on bone turnover (3, 18, 19). However, the exact mechanism by which calcium citrate inhibits bone resorption is not clear. Although urinary calcium rose substantially (suggestive of increased absorbed calcium from the intestinal tract), fasting spth only marginally declined, and serum 1,25-(OH) 2 D and fractional intestinal calcium absorption did not change. One possibility is that the PTH suppression was missed because the rise in serum calcium and suppression in spth were transient. Therefore, it is conceivable that spth returned to baseline by the time it was measured, after an overnight fast. Alternatively, other factors beside parathyroid suppression may have contributed to suppressed bone resorption. One possible factor is alkali load delivered by calcium citrate. Although modest, there was a marginal increase in urinary ph, significantly higher urinary citrate, and lower urinary ammonium. Another potential explanation is that calcium itself might directly affect bone resorption, mediated via calcium sensor receptor protein regulating osteoclastic function (20). Comparison of combined treatment (potassium citrate plus calcium citrate) with calcium citrate alone afforded an assessment of the action of potassium citrate on a high calcium intake. Compared with calcium citrate alone, combined treatment significantly increased urinary ph and citrate and significantly lowered urinary ammonium, thus indicating provision of alkali load by potassium citrate during high calcium intake. However, urinary calcium was numerically lower but not significantly different from the calcium citrate alone, suggesting that the hypocalciuric action of potassium alkali (7, 8) was largely lost during a high-calcium diet. The inhibition of PTH secretion by calcium citrate may have contributed to the attenuation of the hypocalciuric action of potassium citrate, although there are no direct studies to support this theory. As on a basal diet, potassium citrate did not change bone markers during high calcium intake, although a subtle effect on bone could not be excluded. The effect of calcium citrate in the setting of high alkali intake was discerned by comparing combined treatment (potassium citrate plus calcium citrate) with potassium citrate alone. Compared with potassium citrate alone, combined treatment significantly increased serum and urinary calcium, and decreased fasting spth, indicating that calcium citrate suppresses parathyroid function by increasing absorbed calcium during high alkali intake. Moreover, urinary citrate was significantly greater, and urinary ph was numerically higher, compared with potassium citrate. Thus, the alkali load delivered by combined treatment was slightly greater than that delivered by potassium citrate alone, probably from the mild alkalinizing action of calcium citrate. Urinary NTX significantly declined, but the other two markers of bone resorption did not. Thus, calcium citrate on high alkali intake probably exerted a bone protective action by the same mechanism(s) as on a basal diet.
6 Sakhaee et al. K Citrate and Ca Citrate in Postmenopausal Women J Clin Endocrinol Metab, June 2005, 90(6): The most prominent effects of combined treatment were displayed when compared with placebo. Combined treatment significantly increased serum and urinary calcium and marginally reduced fasting spth, suggestive of suppression of parathyroid function by absorbed calcium from calcium citrate. Moreover, combined treatment significantly increased urinary ph and citrate and reduced urinary ammonium, indicative of alkali load from potassium citrate. All three markers of bone resorption decreased. Thus, on a basal diet (simulated by placebo), combined treatment conferred a bone protective action probably by the dual action of calcium citrate and potassium citrate. A noteworthy finding here was that markers of bone formation were not altered by any treatment. The result probably reflects the short duration of treatment (2 wk), which is insufficient to elicit adequate osteoblastic response. The results of this study may not be applied to use of other calcium salts. Calcium citrate alone was recently shown to be significantly more effective than calcium carbonate alone in reducing markers of bone resorption in postmenopausal women, without differing changes in spth (21). In summary, potassium citrate alone conferred an alkali load, thereby reducing urinary calcium and potentially causing calcium retention. Calcium citrate alone probably suppressed parathyroid function, conferred a mild alkali load, and reduced bone resorption. Potassium citrate in a setting of a high calcium intake (with calcium citrate) conferred an alkali load but lacked hypocalciuric action. Calcium citrate in a setting of high alkali intake (with potassium citrate) suppressed parathyroid function and conferred a slightly greater alkali load. In a basal dietary setting (simulated by placebo), combined treatment reduced bone resorption by dual effects of alkali load from potassium citrate and of absorbed calcium from calcium citrate. Combined treatment may be considered among postmenopausal women with impaired intestinal calcium absorption or who are on a habitually high-animal-protein diet, although greater doses of potassium alkali may be needed. Future studies must be conducted to elucidate the long-term effects of the combined treatment on bone mineral density and fracture risk. Acknowledgments We acknowledge the expertise of Beverley Adams-Huet M.Sc., John Poindexter, and the nursing staff, Bionutrition Core, and Informatics Core at the GCRC of the University of Texas Southwestern Medical Center. Received December 14, Accepted February 24, Address all correspondence and requests for reprints to: Khashayar Sakhaee, M.D., 5323 Harry Hines Boulevard, Dallas, Texas khashayar.sakhaee@ .swmed.edu. This work was supported by research grants from the National Institutes of Health (M01-RR00633, P01-DK20543, and T32-DK07307). C.Y.C.P. was the principal investigator for the new drug application of Urocit-K that was approved by the Federal Drug Administration for the prevention of uric acid stones and calcium stones associated with hypocitraturia. The University of Texas Southwestern Medical Center, the sponsor of Urocit-K and Citracal, has a licensing agreement with the Mission Pharmacal Company, which markets these drugs. The Mission Pharmacal Company kindly provided all study drugs for this study, including placebo medications, free of charge. It did not provide any funding or other support. None of the authors own equity in the Mission Pharmacal Company or serve as a consultant or member of its board. References 1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285: McKane WR, Khosla S, Egan KS, Robins SP, Burritt MF, Riggs BL 1996 Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab 81: Riggs BL, O Fallon WM, Muhs J, O Connor MK, Kumar R, Melton 3rd J 1998 Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 13: Sebastian A, Harris ST, Ottaway JH, Todd KM, Morris Jr C 1994 Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med 330: Marangella M, Di Stefano M, Casalis S, Berutti S, D Amelio P, Isaia GC 2004 Effects of potassium citrate supplementation on bone metabolism. Calcif Tissue Int 74: Blair HC, Teitelbaum SL, Ghiselli R, Gluck S 1989 Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245: Sakhaee K, Alpern R, Jacobson HR, Pak CY 1991 Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab 72: Lemann Jr J 1999 Relationship between urinary calcium and net acid excretion as determined by dietary protein and potassium: a review. Nephron 81(Suppl 1): Bushinsky DA 1996 Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Am J Physiol 271:F216 F Abrams SA, Esteban NV, Vieira NE, Yergey AL 1991 Dual tracer stable isotopic assessment of calcium absorption and endogenous fecal excretion in low birth weight infants. Pediatr Res 29: Abrams SA 1999 Using stable isotopes to assess mineral absorption and utilization by children. Am J Clin Nutr 70: Perlman A, Wu L 2002 A class of conditional tests for a multivariate one-sided alternative. J Stat Plann Inference 107: Yeh BI, Sun TJ, Lee JZ, Chen HH, Huang CL 2003 Mechanism and molecular determinants for regulation of rabbit transient receptor potential type 5 (TRPV5) by extracellular ph. J Biol Chem 278: Preminger GM, Sakhaee K, Pak CY 1987 Hypercalciuria and altered intestinal calcium absorption occurring independently of vitamin D in incomplete distal renal tubular acidosis. Metabolism 36: Sutton RA, Wong NL, Dirks JH 1979 Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 15: Panel on Macronutrients, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes 2002 Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Washington, DC: National Academies Press; Ince BA, Anderson EJ, Neer RM 2004 Lowering dietary protein to U.S. recommended dietary allowance levels reduces urinary calcium excretion and bone resorption in young women. J Clin Endocrinol Metab 89: Ruml LA, Sakhaee K, Peterson R, Adams-Huet B, Pak CY 1999 The effect of calcium citrate on bone density in the early and mid-postmenopausal period: a randomized placebo-controlled study. Am J Ther 6: Prestwood KM, Pannullo AM, Kenny AM, Pilbeam CC, Raisz LG 1996 The effect of a short course of calcium and vitamin D on bone turnover in older women. Osteoporos Int 6: Zaidi M, Adebanjo OA, Moonga BS, Sun L, Huang CL 1999 Emerging insights into the role of calcium ions in osteoclast regulation. J Bone Miner Res 14: Kenny AM, Prestwood KM, Biskup B, Robbins B, Zayas E, Kleppinger A, Burleson JA, Raisz LG 2004 Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women. Osteoporos Int 15: JCEM is published monthly by The Endocrine Society ( the foremost professional society serving the endocrine community.
Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationAnnie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu
Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationNew aspects of acid-base disorders
New aspects of acid-base disorders I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College of Medicine
More informationCALCIUM INTAKE MAY be one of the many factors that
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):707 711 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-1380 Lack of Effect of Calcium Intake
More informationMEDICAL STONE MANAGEMENT MADE EASY PRACTICAL ADVICE
MEDICAL STONE MANAGEMENT MADE EASY PRACTICAL ADVICE Comprehensive Kidney Stone Center at Duke University Medical Center Durham, North Carolina Glenn M. Preminger, M.D. UCLA State-of-the Art Urology 02
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationImportant aspects of acid-base disorders
Important aspects of acid-base disorders I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationRISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES Review of NASA s Evidence Reports on Human Health Risks
Mayo Clinic O Brien Urology Research Center RISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES 2017 Review of NASA s Evidence Reports on Human Health Risks John C Lieske, MD July 27, 2017 What types
More informationManagement of recurrent kidney stones requires both
Comparative Value of Orange Juice versus Lemonade in Reducing Stone-Forming Risk Clarita V. Odvina Charles and Jane Pak Center for Mineral Metabolism and Clinical Research and Department of Internal Medicine,
More informationThe Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels
17.6 The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels Partially embedded in the posterior surface of the lateral lobes of the thyroid gland
More informationExposure to the microgravity environment of space
Urolithiasis/Endourology Reduction of Renal Stone Risk by Potassium-Magnesium Citrate During 5 Weeks of Bed Rest Joseph E. Zerwekh,* Clarita V. Odvina, Lisa-Ann Wuermser and Charles Y. C. Pak From the
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationMetabolic Stone Work-Up For Stone Prevention. Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department
Metabolic Stone Work-Up For Stone Prevention Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department Faculty/Presenter Disclosure Slide Faculty: Hazem Elmansy Relationships with
More informationHigh Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker
J Bone Metab 214;21:189-194 http://dx.doi.org/1.115/jbm.214.21.3.189 pissn 2287-6375 eissn 2287-729 Original Article High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism
Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationDietary Protein and Bone Health Emphasis: Animal Protein
USDA-ARS Human Nutrition Research Centers Dietary Protein and Bone Health Emphasis: Animal Protein Z.K. (Fariba) Roughead, PhD, RD Research Nutritionist USDA-ARS Grand Forks Human Nutrition Research Center
More informationSodium and Potassium Intake and Cardiovascular and Bone Health:
Sodium and Potassium Intake and Cardiovascular and Bone Health: How Important is the Ratio? Connie M. Weaver Nutrition Science Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationMajor intra and extracellular ions Lec: 1
Major intra and extracellular ions Lec: 1 The body fluids are solutions of inorganic and organic solutes. The concentration balance of the various components is maintained in order for the cell and tissue
More informationChapter 26 Fluid, Electrolyte, and Acid- Base Balance
Chapter 26 Fluid, Electrolyte, and Acid- Base Balance 1 Body Water Content Infants: 73% or more water (low body fat, low bone mass) Adult males: ~60% water Adult females: ~50% water (higher fat content,
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationAcid-base balance is one of the most important of the body s homeostatic mechanisms Acid-base balance refers to regulation of hydrogen ion (H + )
Acid-base balance is one of the most important of the body s homeostatic mechanisms Acid-base balance refers to regulation of hydrogen ion (H + ) concentration in body fluids Precise regulation of ph at
More informationAcid-Base Balance 11/18/2011. Regulation of Potassium Balance. Regulation of Potassium Balance. Regulatory Site: Cortical Collecting Ducts.
Influence of Other Hormones on Sodium Balance Acid-Base Balance Estrogens: Enhance NaCl reabsorption by renal tubules May cause water retention during menstrual cycles Are responsible for edema during
More informationPrinciples of Anatomy and Physiology
Principles of Anatomy and Physiology 14 th Edition CHAPTER 27 Fluid, Electrolyte, and Acid Base Fluid Compartments and Fluid In adults, body fluids make up between 55% and 65% of total body mass. Body
More informationCHAPTER 27 LECTURE OUTLINE
CHAPTER 27 LECTURE OUTLINE I. INTRODUCTION A. Body fluid refers to body water and its dissolved substances. B. Regulatory mechanisms insure homeostasis of body fluids since their malfunction may seriously
More informationMedical Approach to Nephrolithiasis. Seth Goldberg, MD September 15, 2017 ACP Meeting
Medical Approach to Nephrolithiasis Seth Goldberg, MD September 15, 2017 ACP Meeting DISCLOSURES Seth Goldberg, MD Assistant Professor of Medicine Research support Abbott Kadmon Otsuka Pfizer Introduction
More informationHypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance
Normal value Hypocalcemia Serum calcium Total mg/dl Ionized mg/dl Cord blood 9.0 ~ 11.5 5.0 ~ 6.o New born (1 st 24 hrs) 9.0 ~ 10.6 4.3 ~ 5.1 24~ 48 hrs 7.0 ~12.0 4.0 ~4.7 Child 8.8 ~10.8 4.8 ~4.92 There
More informationChapter 27: WATER, ELECTROLYTES, AND ACID-BASE BALANCE
Chapter 27: WATER, ELECTROLYTES, AND ACID-BASE BALANCE I. RELATED TOPICS Integumentary system Cerebrospinal fluid Aqueous humor Digestive juices Feces Capillary dynamics Lymph circulation Edema Osmosis
More informationUrinary Calculus Disease. Urinary Stones: Simplified Metabolic Evaluation. Urinary Calculus Disease. Urinary Calculus Disease 2/8/2008
Urinary Stones: Simplified Metabolic Evaluation Marshall L. Stoller, M.D. Professor and Vice Chairman Department of Urology University of California San Francisco Incidence: 7-21/10,000 3 men: 1 woman
More informationAcid-Base Balance Dr. Gary Mumaugh
Acid-Base Balance Dr. Gary Mumaugh Introduction Acid-base balance is one of the most important of the body s homeostatic mechanisms Acid-base balance refers to regulation of hydrogen ion (H + ) concentration
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationRelative bioavailability of calcium-rich dietary sources in the elderly 1 4
Relative bioavailability of calcium-rich dietary sources in the elderly 1 4 Ligia Martini and Richard J Wood ABSTRACT Background: The recent increase in the dietary calcium recommendation from 800 to 1200
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationPotassium Citrate Supplementation Results in Sustained Improvement in Calcium Balance in Older Men and Women
ORIGINAL ARTICLE JBMR Potassium Citrate Supplementation Results in Sustained Improvement in Calcium Balance in Older Men and Women Kendall F Moseley, 1 Connie M Weaver, 2 Lawrence Appel, 3 Anthony Sebastian,
More informationHypercalcemia. Hypercalcemia: When to Worry, When to Treat! Mineral Metabolism : A Short Course
Hypercalcemia: When to Worry, When to Treat! Michael A. Levine has no financial relationships to disclose or Conflicts of Interest to resolve. Michael A. Levine, M.D. This presentation will not involve
More informationRENAL FUNCTION An Overview
RENAL FUNCTION An Overview UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ. Temple 1 Kidneys
More informationPresented by: Michelle Darr February 5, 2013
Total calcium absorption is similar from infant formulas with and without prebiotics and exceeds that in human milk-fed infants Penni D Hicks1, 2,3*, Keli Hawthorne1, 2, Carol L Berseth3, John D Marunycz3,
More informationContemporary Nutrition 6 th. th ed. Chapter 9 Minerals
Contemporary Nutrition 6 th th ed. Chapter 9 Minerals Minerals Various functions in the body Major Minerals Require >100 mg /day Calcium, phosphorus Trace Minerals Require < 100 mg/day Iron, zinc Bioavailability
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More informationPharmacological Treatment of Endocrinopathies
Pharmacological Treatment of Endocrinopathies Progress in Basic and Clinical Pharmacology Vol. 5 Series Editors P. Lomax, Los Angeles, Calif. E.S. Vesell, Hershey, Pa. KARGER Basel München Paris. London
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationEFFECT OF DIETARY CATION-ANION DIFFERENCE ON MINERAL BALANCE IN WEANLING HORSES. Authors:
EFFECT OF DIETARY CATION-ANION DIFFERENCE ON MINERAL BALANCE IN WEANLING HORSES 1999 Animal Science Research Report Authors: Story in Brief Pages 182-188 S.R. Cooper, D.R. Topliff, D.W. Freeman, J.E. Breazile
More informationDavid Bruyette, DVM, DACVIM
VCAwestlaspecialty.com David Bruyette, DVM, DACVIM Disorders of calcium metabolism are common endocrine disorders in both dogs and cats. In this article we present a logical diagnostic approach to patients
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationInstrumental determination of electrolytes in urine. Amal Alamri
Instrumental determination of electrolytes in urine Amal Alamri What is the Electrolytes? Electrolytes are positively and negatively chargedions, Found in Within body's cells extracellular fluids, including
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationHYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences
HYPERCALCEMIA Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences ESSENTIALS OF DIAGNOSIS Serum calcium level > 10.5 mg/dl Serum ionized
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationThe antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide
The antihypertensive and diuretic effects of amiloride and of its combination with hydrochlorothiazide The hypotensive effect as well as changes in serum electrolytes and uric acid of amiloride (AM) and
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationOMICS Journals are welcoming Submissions
OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible
More informationApplying the DRI Framework to Chronic Disease Endpoints
Applying the DRI Framework to Chronic Disease Endpoints Paula R. Trumbo, Ph.D. U.S. Food and Drug Administration Institute of Medicine, Food and Nutrition Board Workshop Development of DRIs, 1994-2004:
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More information"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy
"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy Rebecca S. Sippel, M.D. Assistant Professor Department of Surgery Section of Endocrine Surgery University of Wisconsin Primary Hyperparathyroidism
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationContinuing Education for Pharmacy Technicians Dietary Supplements: Calcium and Vitamin D
1 Continuing Education for Pharmacy Technicians Dietary Supplements: Calcium and Vitamin D Ashley Elliott, PharmD candidate Julie N. Bosler, PharmD McWhorter School of Pharmacy Birmingham, AL Objectives:
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationCalcium Marie Dunford, PhD, MD, Nutrition Consultant, Kingsburg, CA
Calcium Marie Dunford, PhD, MD, Nutrition Consultant, Kingsburg, CA Calcium is an essential mineral and a major nutrient needed for proper bone health. Absorption of calcium in adults is low. Vitamin D
More informationVitamin D. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist
Vitamin D Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Learning objectives Biochemistry and physiology of vitamin D Causes and consequences of vitamin D deficiency Current and anticipated guidelines
More informationChapter 19 The Urinary System Fluid and Electrolyte Balance
Chapter 19 The Urinary System Fluid and Electrolyte Balance Chapter Outline The Concept of Balance Water Balance Sodium Balance Potassium Balance Calcium Balance Interactions between Fluid and Electrolyte
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationSchool of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR
1 School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR URINARY (RENAL) STONE FORMATION An Overview What are Urinary (Renal)
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationOriginal Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
www.ijcem.com/ijcem807001 Original Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism Itoko Hisa 1, Hiroshi Kaji 1, Yoshifumi
More informationUCLA Nutrition Bytes. Title. Permalink. Journal ISSN. Author. Publication Date. Calcium and Hypertension. https://escholarship.org/uc/item/68b658ss
UCLA Nutrition Bytes Title Calcium and Hypertension Permalink https://escholarship.org/uc/item/68b658ss Journal Nutrition Bytes, 4(2) ISSN 1548-601X Author Martinez, Christina Publication Date 1998-01-01
More informationPRIMARY HYPERPARATHYROIDISM PRIMARY HYPERPARATHYROIDISM. Hyperparathyroidism Etiology. Common Complex Insidious Chronic Global Only cure is surgery
ENDOCRINE DISORDER PRIMARY HYPERPARATHYROIDISM Roseann P. Velez, DNP, FNP Francis J. Velez, MD, FACS Common Complex Insidious Chronic Global Only cure is surgery HYPERPARATHYROIDISM PARATHRYOID GLANDS
More informationPhosphate and carbonate salts of calcium support robust bone building in osteoporosis 1 3
AJCN. First published ahead of print May 19, 2010 as doi: 10.3945/ajcn.2009.29085. and carbonate salts of calcium support robust bone building in osteoporosis 1 3 Robert P Heaney, Robert R Recker, Patrice
More informationParathyroid hormone (serum, plasma)
Parathyroid hormone (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Parathyroid hormone (PTH) 1.2 Alternative names Parathormone 1.3 NMLC code 1.4 Description of analyte PTH is an
More informationOF DIETARY CATION-ANION BALANCE ON MINERAL BALANCE IN HORSES. Story In Brief
EFFECf OF DIETARY CATION-ANION BALANCE ON MINERAL BALANCE IN HORSES L. A. Bakerl, D.R. Topliff2, D.W. Freeman2, RG. Teeter3 and I.E. Breazile4 Story In Brief Four mature sedentary geldings were used in
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationVitamin D Deficiency. Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver
Vitamin D Deficiency Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver 50 yo woman referred for osteoporosis What is striking about her
More informationSteven A Abrams, Keli M Hawthorne, and Zhensheng Chen
Supplementation with 1000 IU vitamin D/d leads to parathyroid hormone suppression, but not increased fractional calcium absorption, in 4 8-y-old children: a double-blind randomized controlled trial 1 4
More informationThe Parathyroid Glands
The Parathyroid Glands Bởi: OpenStaxCollege The parathyroid glands are tiny, round structures usually found embedded in the posterior surface of the thyroid gland ([link]). A thick connective tissue capsule
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationOsteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals. Susan J Whiting University of Saskatchewan
Osteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals Susan J Whiting University of Saskatchewan Learning Objectives Understand the 3 critical nutrients for bone:
More information